X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Story Feb. 6 - X4 Pharmaceuticals ... Story Feb. 5 - Viracta Therapeutics: The cancer biotech has closed its doors, laying off all employees and winding down operations. Story Feb. 5 - Frontier ...

Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago. These ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. United Therapeutics beat analysts’ revenue ...

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

The FDA acknowledges the necessity of immunogenicity assays to assess immune responses to components of oligonucleotide therapeutics, particularly those with carriers or conjugates.